Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients

The introduction and the extended clinical use of nilotinib in the first-line treatment of chronic myeloid leukemia have been based on company-sponsored trials. Independent confirmations are extremely important. We report an investigator-sponsored study of nilotinib 300 mg twice daily in 130 chronic...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Haematologica
Main Authors: Castagnetti, Fausto, Breccia, Massimo, Gugliotta, Gabriele, Martino, Bruno, D’Adda, Mariella, Stagno, Fabio, Carella, Angelo Michele, Avanzini, Paolo, Tiribelli, Mario, Trabacchi, Elena, Visani, Giuseppe, Gobbi, Marco, Salvucci, Marzia, Levato, Luciano, Binotto, Gianni, Capalbo, Silvana Franca, Bochicchio, Maria Teresa, Soverini, Simona, Cavo, Michele, Martinelli, Giovanni, Alimena, Giuliana, Pane, Fabrizio, Saglio, Giuseppe, Rosti, Gianantonio, Baccarani, Michele
Formato: Artigo
Idioma:Inglês
Publicado em: Ferrata Storti Foundation 2016
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5046649/
https://ncbi.nlm.nih.gov/pubmed/27470600
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2016.144949
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados